Scrip Asks…What Does 2022 Hold For Biopharma? Part 2: Deal Making, M&A And Financial Markets
More M&A Expected As Biotech Valuations Decline
Following two record-breaking years for biotech fundraising, stock valuations are heading downwards. Biopharma executives and industry experts surveyed by Scrip anticipate big pharma executing more deals and acquisitions in 2022.
You may also be interested in...
In this week's podcast edition of Five Must-Know Things: Scrip asks what 2022 holds for deal-making; Pfizer looks for transactions to add to its top line; Sanofi unworried about JAK threat to Dupixent; what information do healthcare professionals want from pharma; and Amgen looks to its established brands for growth.
Public Company Edition: While panelists at Biotech Showcase argued merging with a special purpose acquisition corporation is not as attractive as it used to be, firms continue to pursue this go-public alternative. Also, Hillstream launched a small IPO and Cytokinetics accessed cash from Royalty Pharma.
With a candidate for ulcerative colitis set to go into Phase III soon with a safety profile that looks cleaner than anti-TNFs and the JAK class, the French biotech could soon be getting some interesting offers.